Søgeresultater - S.R. Schwid

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Cost-effectiveness of disease-modifying therapy for multiple sclerosis

    Cost-effectiveness of disease-modifying therapy for multiple sclerosis af Katia Noyes, Alina Bajorska, A T Chappel, S. R. Schwid, Lahar Mehta, Bianca Weinstock‐Guttman, Robert G. Holloway, Andrew W. Dick

    Udgivet 2011
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  2. 2
    Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis

    Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis af Steven R. Schwid, John Thorpe, Mohammad K. Sharief, Magnhild Sandberg‐Wollheim, Kottil Rammohan, Jeanette Wendt, Hillel S. Panitch, Douglas S. Goodin, David Li, Peter Chang, Gordon Francis

    Udgivet 2005
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  3. 3
    Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

    Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis af Lauren Krupp, Christopher Christodoulou, Patricia Melville, W. F. Scherl, L.-Y. Pai, L.R. Muenz, Dian He, R.H.B. Benedict, Andrew Goodman, Syed Rizvi, S.R. Schwid, Bianca Weinstock‐Guttman, Holly James Westervelt, H. Wishart

    Udgivet 2011
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  4. 4
    Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease

    Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease af Michael A. Schwarzschild, Steven R. Schwid, Kenneth Marek, Arthur Watts, Anthony E. Lang, David Oakes, Ira Shoulson, Alberto Ascherio, Christopher Hyson, Emily Gorbold, Alice Rudolph, Karl Kieburtz, Stanley Fahn, Lisa Gauger, Christopher G. Goetz, John Seibyl, M. Forrest, John Ondrasik

    Udgivet 2008
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  5. 5
    Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

    Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials af Andrew Goodman, François Béthoux, Theodore R. Brown, Randall T. Schapiro, Ron Cohen, Lawrence N. Marinucci, Herbert R. Henney, Andrew R. Blight, Mark Agius, B. G. W. Arnason, F. Béthoux, C. T. Bever, JD Bowen, TR Brown, D. Dietrich, Kelly Edwards, MS Freedman, Mark S. Freedman, NJ Kachuck, MD Kaufman, Marshall J. Keilson, Omar Khan, Lauren Krupp, TP Leist, John Lindsey, F.D. Lublin, MK Mass, D. E. Mattson, Denise McGowan, Robert T. Naismith, Colleen O’Connell, JJ Oger, Hillel S. Panitch, MA Picone, K Rammohan, RT Schapiro, S.R. Schwid, Thomas F. Scott, C Short, BW Thrower, TL Vollmer, Ann Camac, JA Cooper, WF Chumley, Anne H. Cross, RT Dunnigan, JS Gitt, Marij A. Hillen, DR Jeffrey, B. Khatri, Kiren Kresa-Reahl, Seok Whan Moon, Jana Lízrová Preiningerová, Mark Tullman, Bianca Weinstock‐Guttman, DR Wynn

    Udgivet 2015
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:

Søgeredskaber: